0
0
Home » Pharmaceuticals

Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030

The glioblastoma multiforme (GBM) market at $549.1 million in 2020 across the 8MM. This does not include sales of imaging-enhancing agents such as 5-aminolevulinic acid, corticosteroids, or Optune TTF, which often inflate the GBM market. The 8MM are expected to experience moderate growth over the forecast period, at a CAGR of more than 4% during 2021-2030. The growth will be driven by the anticipated launch of eight pipeline agents, of which cancer vaccines and protein kinase inhibitors are the dominating classes.

Growth will be modestly limited by the introduction of biosimilar Avastin (bevacizumab) following its patent expiration, combined with the introduction of pipeline agents such as Bayer’s regorafenib, Kintara Therapeutics’ Val-083, and Kazia Therapeutics paxalisib. These agents will erode bevacizumab shares in the second-line setting due to their explicit exclusion criteria of bevacizumab- and lomustine-treated patients in the recurrence arm of the GBM-AGILE trial.

Overview of the glioblastoma multiforme drug market

Overview of the glioblastoma multiforme drug market

For more insights on this report, download a free report sample

What are the market dynamics in the glioblastoma multiforme drug market?

The major drivers of growth in the forecast period across the 8MM are approvals and launches of high-priced therapeutics during the forecast period in the 8MM, which include two cancer vaccines, three protein kinase inhibitors, and three small-molecule chemotherapies, an increasing number of incident cases of GBM, particularly in the US (due to underlying population growth) and China (due to urbanization) and a high level of unmet need in GBM that warrants faster uptake of the pipeline agents expected to launch during the forecast window, as patients have few other treatment options.

The patent expiration of Avastin and subsequent entry of biosimilars may reduce market traction, resulting in higher discounts from upcoming players like as Bio-Thera Solutions’ BAT1706 for the biosimilar market, increased cost-consciousness will limit reimbursement and the uptake rate of new market entrants, particularly in the 5EU. Moreover, China has made pledges to cut costs, likely to reduce prices further than anticipated in the forecast are the major barriers to growth in the forecast period in the 8MM.

What are the diagnosed incident cases of glioblastoma multiforme in the 8MM?

Global sales are principally attributed to the US due to its larger patient population and higher pricing nature of therapies. The US is expected to retain its position as the largest market for GBM in 2030, consisting of more than 50% of 8MM total sales. GBM patients currently have no curative treatment options and a low survival expectancy; thus, there is the potential for high uptake of any therapy capable of improving survival or QOL in GBM patients. The GBM market was dominated by sales of Avastin and chemotherapy (temozolomide and lomustine, primarily) for patients with recurrent and newly diagnosed GBM, respectively, and makeup approximately 95% of sales across the 8MM market in 2020. Avastin sales will be affected by the introduction of bevacizumab biosimilars in the US, China, 5EU, and Japan beginning in 2023. This will decrease branded Avastin 8MM sales to around a third of its peak levels by 2030.

Who are the major players in the glioblastoma multiforme drugs market?

The current major player in the GBM market, with regards to sales, is Roche’s Avastin. The second major player, concluded on the basis of patient share and pipeline potential as opposed to pricing influence, is Merck & Co. The GBM-AGILE trial pioneers Bayer, Kintara Therapeutics, and Kazia Therapeutics are expected to penetrate the GBM market by introducing regorafenib, Val-083, and paxalisib, respectively.

Glioblastoma multiforme drug market, by key players

Glioblastoma multiforme drug market, by key players

For more insights on key players, download a free report sample

Market report scope

Market Size (Year-2020) $549.1 million
CAGR >4%
Base Year 2020
Forecast Period 2021-2030
Key Types Glioblastoma, Meningioma, Ependymoma, Oligodendroglioma, and CNS Lymphoma
Key Countries The US, France, Germany, Italy, Spain, the UK, Urban China, and Japan
Key Players Roche, Merck & Co., Bayer, Kintara Therapeutics, and Kazia Therapeutics

Scope

This report provides an in-depth analysis of the following:

  • Overview of Glioblastoma Multiforme including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline Glioblastoma Multiforme market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Glioblastoma Multiforme therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II-III).
  • Analysis of the current and future market competition in the global Glioblastoma Multiforme therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Glioblastoma Multiforme therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glioblastoma Multiforme market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global Glioblastoma Multiforme therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Players

Roche/Genentech

Merck & Co

Arbor

NextSource Biotechnology

Heritage Pharmaceuticals (Emcure)

Daiichi Sankyo

Nipro ES Pharma

Bayer

Kazia Therapeutics

Kintara Therapeutics

Epitopoietic Research Corporation

Denovo Biopharma

CNS Pharmaceuticals

Northwest Biotherapeutics

Laminar Pharmaceuticals

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Glioblastoma Multiforme: Executive Summary

1.1 The Glioblastoma Multiforme Market is Forecast to Reach $868.5M by 2030 Across the 8MM

1.2 GBM-AGILE Candidates Set to Penetrate the Market While Merck & Co. Expands its Early-Stage Portfolio and Roche Experiences Erosion

1.3 High Unmet Needs Exist in the GBM Market, Especially in MGMT-Promoter Unmethylated Patients and Unresectable Patients

1.4 Opportunities for New Entrants with Better Markers of Prognosis and Drug Targets

1.5 Novel GBM-AGILE Drug Candidates and Immunotherapies Expected to Launch During the Forecast Period

1.6 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 8MM Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Diagnosed Incident Cases of Brain Cancer

4.4.4 Diagnosed Incident Cases of Brain Cancer by Type

4.4.5 Diagnosed Incident Cases of Glioblastoma by Grade

4.4.6 Diagnosed Incident Cases of Glioblastoma by Origin

4.4.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers

4.4.8 Diagnosed Incident Cases of Glioblastoma by Mutations

4.4.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer

4.5 Discussion

4.5.1 Epidemiological Forecast Insight

4.5.2 COVID-19 Impact

4.6 Epidemiological Forecast for Brain Cancer (2020–2030)

4.6.1 Diagnosed Incident Cases of Brain Cancer

4.6.2 Age-Specific Diagnosed Incident Cases of Brain Cancer

4.6.3 Sex-Specific Diagnosed Incident Cases of Brain Cancer

4.6.4 Diagnosed Incident Cases of Brain Cancer by Type

4.6.5 Diagnosed Incident Cases of Glioblastoma by Grade

4.6.6 Diagnosed Incident Cases of Glioblastoma by Origin

4.6.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers

4.6.8 Diagnosed Incident Cases of Glioblastoma by Mutations

4.6.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer

4.6.10 Limitations of the Analysis

4.6.11 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Identification and Validation of Biomarkers and Drug Targets

7.3 Overcoming the Blood-Brain Barrier to Improve the Efficacy of Treatments

7.4 Better Treatment Options for MGMT Unmethylated and Unresectable Patients

7.5 Differentiating Pseudoprogression and True Progression

9 R&D Strategies

9.1 Overview

9.1.1 The Efficacy of Immunotherapy in GBM

9.1.2 Predictive Biomarkers and Targeted Therapy

9.1.3 Improving Therapy Administration Routes

9.2 Clinical Trials Design

9.2.1 Clinical Endpoints

9.2.2 More Umbrella or Platform Trial Designs

9.2.3 Comparator Arms

10 Pipeline Assessment

10.1 Overview

10.2 Promising Drugs in Clinical Development

11 Pipeline Valuation Analysis

11.1 Overview

11.2 Competitive Assessment

12 Current and Future Players

12.1 Overview

12.2 Deal-Making Trends

13 Market Outlook

13.1 Global Markets

13.1.1 Forecast

13.1.2 Drivers and Barriers – Global Issues

13.2 US

13.2.1 Forecast

13.2.2 Key Events

13.2.3 Drivers and Barriers

13.3 5EU

13.3.1 Forecast

13.3.2 Key Events

13.3.3 Drivers and Barriers

13.4 Japan

13.4.1 Forecast

13.4.2 Key Events

13.4.3 Drivers and Barriers

13.5 China

13.5.1 Forecast

13.5.2 Key Events

13.5.3 Drivers and Barriers

14 Appendix

14.1 Bibliography

14.2 Abbreviations

14.3 Methodology

14.3.1 Forecasting Methodology

14.4 Primary Research – KOLs Interviewed for This Report

14.4.1 KOLs

14.5 Primary Research – Prescriber Survey

14.6 About the Authors

14.6.1 Analyst

14.6.2 Therapy Area Director

14.6.3 Epidemiologist

14.6.4 Managing Epidemiologist

14.6.5 Global Director of Therapy Analysis and Epidemiology

14.6.6 Global Head and EVP of Healthcare Operations and Strategy

14.1 Contact Us

List of Tables

Table 1: Glioblastoma Multiforme: Key Metrics in the 8MM

Table 2: Classification of Key Gliomas and Corresponding Diagnostic Genes

Table 3: Risk Factors and Comorbid Conditions Associated with Brain Cancer

Table 4: Treatment Guidelines for GBM

Table 5: Top 10 Deals by Value, 2019–2021

Table 6: GBM Market – Global Drivers and Barriers, 2020–2030

Table 7: Key Events Impacting Sales for GBM in the US, 2020–2030

Table 8: GBM Market – Drivers and Barriers in the US, 2020–2030

Table 9: Key Events Impacting Sales for GBM in the 5EU, 2020–2030

Table 10: GBM Market – Drivers and Barriers in the 5EU, 2020–2030

Table 11: Key Events Impacting Sales for GBM in Japan, 2020–2030

Table 12: GBM Market – Drivers and Barriers in Japan, 2020–2030

Table 13: Key Events Impacting Sales for GBM in China, 2020–2030

Table 14: GBM Market – Drivers and Barriers in China, 2020–2030

Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global (8MM) Sales Forecast by Country for GBM in 2020 and 2030

Figure 2: Analysis of the Company Portfolio Gap in GBM During the Forecast Period, 2020–2030

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Recurrent GBM During the Forecast Period

Figure 4: Genetic and Molecular Pathogenesis of GBM

Figure 5: 8MM, Diagnosed Incidence of Brain Cancer, Men, Cases Per 100,000 Population All Ages, 2010–2030

Figure 6: 8MM, Diagnosed Incidence of Brain Cancer, Women, Cases Per 100,000 Population All Ages, 2010–2030

Figure 7: 8MM, Sources Used to Forecast Diagnosed Incident Cases Brain Cancer (ICD-10 = C70, C71, C72)

Figure 8: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Brain Cancer (ICD-10 = C70, C71, C72)

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Brain Cancer (ICD-10 = C70, C71, C72) by Type

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Grade (WHO Grading System)

Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Origin

Figure 12: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Biomarkers and Mutations

Figure 13: 8MM, Diagnosed Incident Cases of Brain Cancer, N, Both Sexes, All Ages, 2020

Figure 14: 8MM, Diagnosed Incident Cases of Brain Cancer by Age, N, Both Sexes, 2020

Figure 15: 8MM, Diagnosed Incident Cases of Brain Cancer by Sex, N, All Ages, 2020

Figure 16: 8MM, Diagnosed Prevalent Cases of Brain Cancer by Type, N, Both Sexes, All Ages, 2020

Figure 17: 8MM, Diagnosed Incident Cases of Glioblastoma by Grade, N, Both Sexes, All Ages, 2020

Figure 18: 8MM, Diagnosed Incident Cases of Glioblastoma by Origin, N, Both Sexes, All Ages, 2020

Figure 19: 8MM, Diagnosed Prevalent Cases of Glioblastoma by Biomarkers, N, Both Sexes, All Ages, 2020

Figure 20: 8MM, Diagnosed Prevalent Cases of Glioblastoma by Mutations, N, Both Sexes, All Ages, 2020

Figure 21: 8MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, N, Both Sexes, All Ages, 2020

Figure 22: Overview of the Treatment Algorithm in GBM

Figure 23: Unmet Needs and Opportunities in GBM

Figure 24: Overview of the Development Pipeline in GBM

Figure 25: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for GBM in the 8MM During the Forecast Period

Figure 26: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Temodar, in Newly Diagnosed GBM

Figure 27: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Gleostine, in Recurrent GBM

Figure 28: Analysis of the Company Portfolio Gap in GBM During the Forecast Period

Figure 29: Global (8MM) Sales Forecast by Country for GBM in 2020 and 2030

Figure 30: Sales Forecast by Class for GBM in the US in 2020 and 2030

Figure 31: Sales Forecast by Class for GBM in the 5EU in 2020 and 2030

Figure 32: Sales Forecast by Class for GBM in Japan in 2020 and 2030

Figure 33: Sales Forecast by Class for GBM in China in 2020 and 2030

Frequently Asked Questions

GlobalData valued the glioblastoma multiforme (GBM) market at $549.1 million in 2020 across the 8MM.

The 8MM are expected to experience low growth for the glioblastoma multiforme market over the forecast period, at a CAGR of more than 4% during 2021-2030.

The major player in the market are Roche, Merck & Co., Bayer, Kintara Therapeutics, and Kazia Therapeutics.

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports